- GLP-1 pill: Eli Lilly says its oral orforglipron showing “promising results” Axios
- Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar The New York Times
- A very good day for Lilly, and a bad day for Novo statnews.com
- Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Eli Lilly and Company
- Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk. Barron’s
